[1]
Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. American journal of hematology. 2015 Dec:90(12):1171-8. doi: 10.1002/ajh.24200. Epub
[PubMed PMID: 26769125]
[2]
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19:127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15
[PubMed PMID: 26980727]
[3]
Ma S. Risk Factors of Follicular Lymphoma. Expert opinion on medical diagnostics. 2012 Jul 1:6(4):323-333
[PubMed PMID: 22754588]
Level 3 (low-level) evidence
[4]
Husson H, Carideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, Donovan JW, Chillemi AC, O'Connell P, Freedman AS. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002 Jan 1:99(1):282-9
[PubMed PMID: 11756183]
[5]
Kridel R, Sehn LH, Gascoyne RD. Can histologic transformation of follicular lymphoma be predicted and prevented? Blood. 2017 Jul 20:130(3):258-266. doi: 10.1182/blood-2017-03-691345. Epub 2017 Apr 13
[PubMed PMID: 28408460]
[6]
Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, Bierman PJ, Bast MA, Daley DT, Armitage JO. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995 Jun 15:85(12):3671-8
[PubMed PMID: 7780151]
[7]
Takata K, Miyata-Takata T, Sato Y, Yoshino T. Pathology of follicular lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2014:54(1):3-9
[PubMed PMID: 24942941]
[8]
Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. American journal of hematology. 2018 Feb:93(2):296-305. doi: 10.1002/ajh.24937. Epub
[PubMed PMID: 29314206]
[9]
Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. The Journal of clinical investigation. 2012 Oct:122(10):3424-31. doi: 10.1172/JCI63186. Epub 2012 Oct 1
[PubMed PMID: 23023713]
[10]
Miao Y, Hu S, Lu X, Li S, Wang W, Medeiros LJ, Lin P. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. Human pathology. 2016 Dec:58():72-77. doi: 10.1016/j.humpath.2016.07.025. Epub 2016 Aug 18
[PubMed PMID: 27544800]
Level 3 (low-level) evidence
[11]
Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, Hasserjian RP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. The American journal of surgical pathology. 2005 Nov:29(11):1490-6
[PubMed PMID: 16224216]
[12]
Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. British journal of haematology. 2014 Mar:164(5):659-67. doi: 10.1111/bjh.12675. Epub 2013 Nov 26
[PubMed PMID: 24274024]
[13]
McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, Marcus R, Montoto S, Ramsay A, Wong WL, Ardeshna K, Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH), British Society for Haematology Committee. Guidelines on the investigation and management of follicular lymphoma. British journal of haematology. 2012 Feb:156(4):446-67. doi: 10.1111/j.1365-2141.2011.08969.x. Epub 2011 Dec 23
[PubMed PMID: 22211428]
[14]
Dada R. Diagnosis and management of follicular lymphoma: A comprehensive review. European journal of haematology. 2019 Sep:103(3):152-163. doi: 10.1111/ejh.13271. Epub 2019 Jul 4
[PubMed PMID: 31270855]
[15]
Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Applied immunohistochemistry & molecular morphology : AIMM. 2013 Mar:21(2):116-31. doi: 10.1097/PAI.0b013e31825d550a. Epub
[PubMed PMID: 22820658]
[16]
Mittal M, Puri A, Nangia R, Sachdeva A. Follicular lymphoma transforming into anaplastic diffuse large B-cell lymphoma of oral cavity: A case report with review of literature. Journal of oral and maxillofacial pathology : JOMFP. 2015 Sep-Dec:19(3):379-84. doi: 10.4103/0973-029X.174617. Epub
[PubMed PMID: 26980969]
Level 3 (low-level) evidence
[17]
Xu P, Jiang Y, Guan C, Shao X, Chen M, Ouyang J, Chen B. Development of follicular lymphoma after treatment of diffuse large B-cell lymphoma: two case reports with review of literature. International journal of clinical and experimental pathology. 2018:11(1):324-332
[PubMed PMID: 31938115]
Level 3 (low-level) evidence
[18]
Nathwani BN, Winberg CD, Diamond LW, Bearman RM, Kim H. Morphologic criteria for the differentiation of follicular lymphoma from florid reactive follicular hyperplasia: a study of 80 cases. Cancer. 1981 Oct 15:48(8):1794-806
[PubMed PMID: 7026023]
Level 3 (low-level) evidence
[19]
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal of the National Comprehensive Cancer Network : JNCCN. 2021 Nov:19(11):1218-1230. doi: 10.6004/jnccn.2021.0054. Epub
[PubMed PMID: 34781267]
[20]
Vargo JA, Gill BS, Balasubramani GK, Beriwal S. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015 Sep 15:121(18):3325-34. doi: 10.1002/cncr.29491. Epub 2015 Jun 4
[PubMed PMID: 26042364]
[21]
Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A, International Lymphoma Radiation Oncology Group. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics. 2014 May 1:89(1):49-58. doi: 10.1016/j.ijrobp.2014.01.006. Epub
[PubMed PMID: 24725689]
[22]
Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A, ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). International journal of radiation oncology, biology, physics. 2014 Jul 15:89(4):854-62. doi: 10.1016/j.ijrobp.2013.05.005. Epub 2013 Jun 18
[PubMed PMID: 23790512]
[23]
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011 Jul:100(1):86-92. doi: 10.1016/j.radonc.2011.05.013. Epub 2011 Jun 12
[PubMed PMID: 21664710]
Level 1 (high-level) evidence
[24]
Hoskin P, Popova B, Schofield O, Brammer C, Robinson M, Brunt AM, Madhavan K, Illidge T, Gallop-Evans E, Syndikus I, Clifton-Hadley L, Kirkwood AA. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. The Lancet. Oncology. 2021 Mar:22(3):332-340. doi: 10.1016/S1470-2045(20)30686-0. Epub 2021 Feb 1
[PubMed PMID: 33539729]
Level 1 (high-level) evidence
[25]
Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, Illidge TM, Eich HT, Hoppe BS, Dabaja B, Ng AK, Kirova Y, Berthelsen AK, Dieckmann K, Yahalom J, Specht L. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International journal of radiation oncology, biology, physics. 2020 Aug 1:107(5):909-933. doi: 10.1016/j.ijrobp.2020.03.019. Epub 2020 Apr 7
[PubMed PMID: 32272184]
Level 3 (low-level) evidence
[26]
Barzenje DA, Cvancarova Småstuen M, Liestøl K, Fosså A, Delabie J, Kolstad A, Holte H. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. PloS one. 2015:10(7):e0131158. doi: 10.1371/journal.pone.0131158. Epub 2015 Jul 6
[PubMed PMID: 26147646]
[27]
Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010 Aug 15:116(16):3843-51. doi: 10.1002/cncr.25149. Epub
[PubMed PMID: 20564102]
[28]
Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019 Jan 17:133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16
[PubMed PMID: 30446493]
[29]
Chan EK, Fung S, Gospodarowicz M, Hodgson D, Wells W, Sun A, Pintile M, Tsang RW. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. International journal of radiation oncology, biology, physics. 2011 Dec 1:81(5):e781-6. doi: 10.1016/j.ijrobp.2010.10.013. Epub 2010 Dec 16
[PubMed PMID: 21167657]
[30]
Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International journal of radiation oncology, biology, physics. 2019 Jul 1:104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004. Epub 2019 Mar 8
[PubMed PMID: 30858143]
[31]
Grignano É, Deau-Fischer B, Loganadane G, Breton M, Burroni B, Bouscary D, Kirova YM. Radiotherapy of relapse-refractory follicular lymphoma. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2018 Apr:22(2):126-130. doi: 10.1016/j.canrad.2017.09.003. Epub 2018 Feb 22
[PubMed PMID: 29477304]
[32]
van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology. American Society of Hematology. Education Program. 2016 Dec 2:2016(1):323-330
[PubMed PMID: 27913498]
[34]
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1:104(5):1258-65
[PubMed PMID: 15126323]
[35]
Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Jun 10:28(17):2902-13. doi: 10.1200/JCO.2009.26.1693. Epub 2010 Apr 12
[PubMed PMID: 20385990]
[36]
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. The Lancet. Oncology. 2014 Apr:15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4
[PubMed PMID: 24602760]
Level 2 (mid-level) evidence